Methamphetamine Treatment Options

You want help with methamphetamine, and someone is offering either a pill that does not exist or a weekend to sweat it out alone. Methamphetamine use disorder has effective treatment. The treatment is not a medicine with FDA approval for this condition. NIDA says there is no FDA-approved medication for methamphetamine use disorder or for any other stimulant use disorder. The same page says effective behavioral treatments exist. The best-studied of them, and the one most associated with treatment success in NIDA's summary, is contingency management. Other approaches with evidence include cognitive behavioral therapy, group support, and motivational interviewing. What follows is that picture at a high level. It is not a home detox plan, and it is not a set of instructions for running an incentive program yourself.

If someone has chest pain, a seizure, a stroke symptom, severe agitation, or trouble breathing, call 911. If the crisis is despair, hopelessness, or thoughts of suicide, call or text 988.

What treatment is being asked to do

NIDA describes methamphetamine as a lab-made stimulant with a high potential for addiction. Repeated use can lead to a stimulant use disorder. Health effects are on the substance overview. What follows stays on care. NIDA's principles guide says addiction to prescription stimulants, which affect the same brain systems as cocaine, is treated with behavioral therapies because medicines for that addiction are not available. Methamphetamine sits in the same gap. A program that advertises a methadone-like medicine for methamphetamine is describing a product that does not have FDA approval for this use. NIDA funds studies of possible medicines. A study is not an approval. Ask what is offered today.

SAMHSA's January 2025 advisory on contingency management says the same thing about the medication gap, and it calls contingency management a primary intervention for stimulant use disorders in the absence of an FDA-approved medicine. The advisory's count is broad: more than 4 million people who meet criteria for a stimulant use disorder, which it defines as cocaine, methamphetamine, or prescription stimulants, citing SAMHSA's 2024 data. That figure is not a methamphetamine-only count. It is the reason the agency treats this behavioral treatment as urgent.

Contingency management, in a clinic

Contingency management gives a tangible incentive when a specific behavior is objectively verified, and it withholds or resets the incentive when the behavior does not occur. SAMHSA describes the targets as abstinence from a specific substance, treatment attendance, or medication adherence. The verification for abstinence-focused programs is a drug test, done by the program. The point is immediate reinforcement of the new behavior.

NIDA's public description of incentives includes prizes, cash, vouchers, or gift cards, offered to help people avoid methamphetamine and stay in treatment. SAMHSA's grant rules are narrower than that sentence, and the difference matters. For recipients of a SAMHSA grant that actually authorizes contingency management, the January 2025 advisory allows a motivational incentive value of up to $750 per patient per year, under safeguards in the advisory. Incentives are supposed to be items, or vouchers or gift cards for items and services that support recovery. Cash payments are not permitted with those grant funds. The advisory says this funding change applies to State Opioid Response and Tribal Opioid Response grants, subject to grant terms, not to every clinic in the country. An older $75 cap is what many programs still remember. If a program tells you it cannot offer incentives, ask whether that is a clinical choice, a grant rule, or an outdated cap.

Two structures show up in the research SAMHSA summarizes. Prize-based contingency management uses a chance draw, with many small wins and rare larger ones. Voucher-based contingency management uses a set amount that typically rises when the behavior happens again and resets when it does not. SAMHSA says incentives work better when they are timely. The testing, the schedule, and the safeguards are clinical. A homemade reward chart is not this treatment, and it is not a reason to skip a program that offers the real protocol.

The other therapies worth naming

Cognitive behavioral therapy helps people notice the thoughts and situations that lead to use and practice other responses. Motivational interviewing works on ambivalence about change. Group support adds other people who are working on the same problem. NIDA lists all three, alongside contingency management, as evidence-based behavioral approaches for methamphetamine use disorder. The separate therapist-led framework NIDA describes for methamphetamine and cocaine is the Matrix Model guide. It is not a synonym for any one of those three. A program should be able to say which of them are on the schedule this week, who leads them, and whether drug testing is tied to an incentive protocol or is only a house rule.

Low-intensity drug education is not the same list. NIDA's outpatient chapter warns that some low-intensity programs offer little more than education.

Mental health symptoms change the week. Psychosis, severe anxiety, and depression can be effects of the drug and can also be separate illnesses that need their own care. How to ask whether both are treated in the same plan is the dual-diagnosis guide. Do not wait on a group therapy slot if someone is acutely paranoid, violent, or unable to care for themselves. That needs emergency help.

Withdrawal is a clinical problem

NIDA says people who use methamphetamine repeatedly can have withdrawal symptoms when they stop, even if they do not meet criteria for a stimulant use disorder. The symptoms it lists are depression, anxiety, irritability, pain and discomfort, sleep problems, cravings, and trouble concentrating. They peak 2 to 3 days after the last use and may last about a week. After that acute stretch, low mood, anxiety, and cravings can continue for months.

That timeline is educational. It is not a schedule for quitting in a bedroom. The mood crash is the part families underestimate. Depression after stopping can be severe. Thoughts of suicide belong on the crisis line above, and on emergency help if a person is about to act. Psychosis, including hallucinations and delusions, can occur with methamphetamine use and can return with heavy drinking or stress even after the drug is gone. During an episode the person can be dangerous to themselves or someone else. Get emergency help.

Alcohol withdrawal and a sudden benzodiazepine stop can cause seizures and can kill. Methamphetamine withdrawal is a different medical picture, which is why some people are told to "just stop." "Just stop" skips the depression, the psychosis, and the overdose risk if use starts again, especially if the supply contains fentanyl. The contrast with alcohol and benzodiazepines, and the pointer toward professional behavioral care, is the detox guide. Get an assessment. Do not build a home protocol from a timeline.

Overdose, including an opioid you did not mean to take

NIDA, citing CDC research, says methamphetamine is the second most common drug found in people who die of overdose, after synthetic opioids. Deaths happen from methamphetamine alone and from methamphetamine combined with fentanyl or heroin. Some people take them together on purpose. Sometimes an opioid is in the methamphetamine without being announced.

Slowed or stopped breathing is the clue that an opioid may be involved. NIDA says experts recommend giving an opioid overdose reversal medicine, such as naloxone or nalmefene, to anyone with that sign. Get emergency help either way. The practical version is the overdose and naloxone guide. Why a stimulant plan and an opioid plan sometimes have to exist together, including medicines for opioid use disorder if that disorder is also present, is the fentanyl guide. Those medicines do not treat methamphetamine use disorder. They treat the opioid part.

What to ask before you enroll

1. Is there contingency management here, and is it prize-based, voucher-based, or a different incentive?
2. If incentives are offered, are they tied to a verified behavior, and are they within the rules of whoever funds them?
3. Which of cognitive behavioral therapy, motivational interviewing, and group support happen every week?
4. What do you do if I arrive in psychosis, or with chest pain?
5. If opioids may be in the supply, is naloxone available, and is opioid use disorder treated here too?

Search FindTreatment.gov and ask the behavioral-therapy questions on the phone. Call or text (800) 653-9376 if you want help talking through programs that offer contingency management or another behavioral treatment for methamphetamine, and what an assessment should cover.

Additional Resources

Sources cited on this page:

• NIDA: Methamphetamine research topic
• SAMHSA Advisory: Using SAMHSA funds to implement evidence-based contingency management services (PEP24-06-001)
• NIDA: Principles of Drug Addiction Treatment, third edition
• SAMHSA FindTreatment.gov
• 988 Suicide & Crisis Lifeline

Common Questions